MARKET

MESO

MESO

Mesoblast
NASDAQ
18.16
+0.12
+0.67%
After Hours: 18.16 0 0.00% 16:10 01/02 EST
OPEN
18.29
PREV CLOSE
18.04
HIGH
18.46
LOW
17.90
VOLUME
196.49K
TURNOVER
--
52 WEEK HIGH
22.00
52 WEEK LOW
9.61
MARKET CAP
2.33B
P/E (TTM)
-21.4733
1D
5D
1M
3M
1Y
5Y
1D
Mesoblast chair Jane Bell to transition out of role, Philip Facchina to succeed
TipRanks · 1d ago
Mesoblast Chair Jane Bell To Retire; Appoints Philip Facchina As Non-executive Chair
NASDAQ · 1d ago
Mesoblast Appoints Philip Facchina as Chair and Lyn Cobley as Audit Chair
Reuters · 1d ago
MESOBLAST ANNOUNCES CHANGES TO BOARD OF DIRECTORS' LEADERSHIP ROLES
Reuters · 1d ago
Mesoblast Ltd Files for Offering of Upto $250M ADS Representing Ordinary Shares
Benzinga · 12/31/2025 11:34
Mesoblast Secures $125 Million Five-Year Credit Line from Major Shareholder
Reuters · 12/29/2025 23:57
Mesoblast Retires Senior Debt with Non-Dilutive, Lower Cost, Five-Year Credit Line
Barchart · 12/29/2025 17:57
Weekly Report: what happened at MESO last week (1222-1226)?
Weekly Report · 12/29/2025 10:26
More
About MESO
Mesoblast Limited is an Australia-based company. The Company is engaged in developing allogeneic (off-the-shelf) cellular medicines for the treatment of severe and life-threatening inflammatory conditions. The Company has developing a range of late-stage product candidates, derived from its first and second generation proprietary mesenchymal lineage cell therapy technology platforms therapies for distinct indications. The Company’s Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell (MSC) therapy. Its other product candidate is Revascor (rexlemestrocel-L). Rexlemestrocel-L is second generation mesenchymal lineage precursor cell product platform and is in late-stage development for treatment of: chronic heart failure (chf) and chronic low back pain (clbp) due to degenerative disc disease. The two products have been commercialized in Japan and Europe by the Company's licensees.

Webull offers Mesoblast Ltd (ADR) stock information, including NASDAQ: MESO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MESO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading MESO stock methods without spending real money on the virtual paper trading platform.